Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
Yonsei Medical Journal
;
: 835-842, 2005.
Artículo
en Inglés
| WPRIM
| ID: wpr-80417
ABSTRACT
A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the synergistic effect of an intraperitoneal (i.p.) injection of a chemotherapeutic drug, paclitaxel, and an intratumoral (i.t.) injection of syngeneic bone marrow- derived DCs for the treatment of pre-existing fibrosarcoma. Subcutaneous tumors were established using MCA102 fibrosarcoma cells in syngeneic C57BL/6 mice. The results demonstrated that the combined treatment of paclitaxel chemotherapy and the injection of DCs led to complete tumor regression, in contrast to only partial eradication of the tumors with chemotherapy or DCs alone. Furthermore, the tumor-free mice were able to resist a repeat challenge with the same type of tumor. These findings suggest that a combination therapy of systemic chemotherapy along with the intratumoral administration of DCs is a potent treatment strategy for fibrosarcoma.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fenotipo
/
Trasplante Isogénico
/
Células Dendríticas
/
Células de la Médula Ósea
/
Células Cultivadas
/
Resultado del Tratamiento
/
Paclitaxel
/
Terapia Combinada
/
Línea Celular Tumoral
/
Fibrosarcoma
Límite:
Animales
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS